Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Bactiguard Holding AB ( ($SE:BACTI.B) ).
Bactiguard has revised its trauma license agreement with orthopedic specialist Zimmer Biomet, granting the US group non-exclusive rights to continue commercializing the ZNN Bactiguard-coated trauma nail system in Europe, selected markets in the Middle East and Africa, and Japan, while Bactiguard regains the remaining global rights in the trauma segment. Under the new structure, Bactiguard will keep earning royalties on actual net sales and introduce a quarterly fixed fee that on an annual basis represents at least half of the previous minimum royalty level, with the company stating that the arrangement will not negatively affect 2025 financials or alter its 2030 strategic and financial targets, thereby preserving earnings visibility while potentially giving it greater strategic flexibility over its infection-prevention trauma portfolio in unlicensed markets.
The most recent analyst rating on ($SE:BACTI.B) stock is a Hold with a SEK16.50 price target. To see the full list of analyst forecasts on Bactiguard Holding AB stock, see the SE:BACTI.B Stock Forecast page.
More about Bactiguard Holding AB
Bactiguard Holding AB is a Stockholm-headquartered global MedTech company that develops biocompatible infection-prevention technology based on an ultra-thin noble metal coating to reduce bacterial adhesion and biofilm formation on medical devices. The company partners with leading medical technology manufacturers across five key therapeutic areas—orthopedics, cardiology, neurology, urology and vascular access—and also markets its own wound management products, aiming to lower infection rates, ease pressure on healthcare systems, and combat antimicrobial resistance; its shares are listed on Nasdaq Stockholm’s Mid-Cap segment.
Average Trading Volume: 45,092
Technical Sentiment Signal: Sell
Current Market Cap: SEK695.6M
For detailed information about BACTI.B stock, go to TipRanks’ Stock Analysis page.